MP16: Bladder Cancer: Non-invasive I
221B
Poster and Podium Sessions
Oncology: Bladder/Upper-Tract/Urethral
Information
Continuing Medical Education
CME
Friday, May 3
MP16-01: Replacing ReTUR with Cystoscopy in High-Grade T1 NMIBC Patients: Confirmatory Results from the HuNIRe Trial
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-02: Prognosis of Variant Histology in Non-Muscle Invasive Bladder Cancer with Low Tumor Burden: A Propensity Score-Matched Analysis with Pure Urothelial Carcinoma
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-03: N-803 plus BCG Complete Response rate in NMIBC CIS subjects: BCG refractory, relapsed, checkpoint failure, and chemotherapy failure; updated results (QUILT 3.032)
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-04: Minimal residual disease detection supports high-grade bladder cancer risk-stratification during recommended repeat transurethral resection
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-05: Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a diverse, urban population
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-06: The International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance.
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-07: Urinary minimal residual disease detection predicts recurrence in BCG-unresponsive NIMBC and quantifies molecular response to nadofaragene firadenovec
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-08: Challenging the Paradigm of "BCG Unresponsive" Bladder Cancer: does additional BCG have an effect?
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-09: TRUCE04: A Phase II Clinical Trial of RC48 for High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) (NCT05495724)
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-10: Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in high-risk non-muscle-invasive bladder cancer
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-11: Long-term outcomes of pTa high grade intermediate and high risk bladder cancer patients
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-12: Prognosis and Management of Non-Muscle Invasive Bladder Cancer with Pathologic Finding of Low Grade with Focal High Grade Features
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-13: Analysis of the tumor microenvironment (TME) in High-Grade Ta (HG Ta) Bladder Cancer reveals an immune and stromal enriched subtype which demonstrates poor prognosis with concurrent carcinoma-in situ (CIS)
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-14: A Phase II trial of intravesical Gemcitabine and Docetaxel (GEMDOCE) in the treatment of BCG-naïve non-muscle invasive urothelial carcinoma of the bladder
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-15: Intravesical electromotive mitomycin in patients with bacillus Calmette-Guérin-unresponsive primary high risk non-muscle invasive bladder cancer: an open label, single arm, phase II study
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-16: A cost-effective diagnostic approach of urothelial carcinomas in 2 mL urine samples based on a novel panel of dual methylated DNA markers
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-17: Phase I study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-18: COMBINATION REGIMEN OF INTRAVESICAL DOCETAXEL, GEMCITABINE, AND CISPLATIN IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-19: Comparison of BCG to Gemcitabine/Docetaxel in The Intermediate Risk Group Composed Mostly of TaHG
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B
MP16-20: Final Results of a Phase I, Single-Arm Clinical Trial of the Combination of Durvalumab and Vicineum in BCG Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NCT03258593)
Friday, May 3, 2024 1:00 PM to 3:00 PM
221B